Bone Biologics (BBLG)
Search documents
Bone Biologics (BBLG) - 2019 Q4 - Annual Report
2020-03-28 02:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 For the transition period from _________ to _________ Commission File Number: 000-53078 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdic ...
Bone Biologics (BBLG) - 2019 Q3 - Quarterly Report
2019-11-14 16:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 000-53078 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware 42-1743430 (State or ...
Bone Biologics (BBLG) - 2019 Q2 - Quarterly Report
2019-08-14 14:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 000-53078 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware 42-1743430 (State or othe ...
Bone Biologics (BBLG) - 2019 Q1 - Quarterly Report
2019-05-13 22:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 000-53078 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware 42-1743430 (State or oth ...
Bone Biologics (BBLG) - 2018 Q4 - Annual Report
2019-03-29 18:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 For the transition period from _________ to _________ Commission File Number: 000-53078 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdic ...